ArticleIn vivo (Athens, Greece)

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer.

Jiri Blazek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.